肺癌肝转移：叙述性综述

黄 金富
广州市红十字会医院

摘要

背景：肝转移在肺癌患者中很常见，并且仍然是发病率、死亡率和生活质量下降的重要原因，尽管在过去十年中
肺癌远处转移患者的整体管理取得了相当大的进步。了解肝转移的分子发病机制对于提高该患者群体的生存率、保持功能
和控制症状至关重要。方法：在中国知网、Google Scholar 、PubMed 数据库使用以下搜索词搜索，“肝转移与肺癌和病理
生理学”，“肝转移与肺癌”等。以确定与肺癌肝转移相关的论文。结论：肺癌肝转移的预后较差，对于肺癌肝转移患者
应该提供多学科的治疗选择。

关键词

肺癌；肝转移；肿瘤

参考

[1] Xie S, Xie S, Wu Z, Wu Z, Qi Y, Qi Y, et al.

The metastasizing mechanisms of lung cancer: Recent

advances and therapeutic challenges. Biomed Pharmacother.

2021;138:111450–111450.

[2]Meza R, Meernik C, Jeon J, Cote ML. Lung cancer

incidence trends by gender, race and histology in the United

States, 1973-2010. PloS One. 2015;10:e0121323.

[3]Johnston FM, Johnston FM, Mavros MN, Herman JM,

Joseph M. Herman, Pawlik TM. Local Therapies for Hepatic

Metastases. J Natl Compr Canc Netw. 2013;11:153–60.

[4]Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi

L, Gusani NJ, et al. Epidemiology of liver metastases. Cancer

Epidemiol. 2020;67:101760.

[5]Jiang C, Chunyang Jiang, Na Zhang, Xiaoli Hu,

Hongyan Wang. Tumor-associated exosomes promote lung

cancer metastasis through multiple mechanisms. Mol Cancer.

2021;20:117.

[6]Clinical manifestations of lung cancer [Internet]. [cited

2023 Jan 17]. Available from: https://www.medilib.ir/uptodate/

show/4641

[7] 中华人民共和国国家卫生健康委员会 . 原发性肺癌

诊疗指南（2022 年版）. 中国合理用药探索 . 2022;19:1–28.

[8] Li J, Xu W, Kong F, Sun X, Zuo X. Meta-analysis:

Accuracy of 18FDG PET-CT for distant metastasis staging in

lung cancer patients. Surg Oncol-Oxf. 2013;22:151–5.

[9]Wu W, Liao H, Ye W, Li X, Jian Zhang, Zhang J, et al.

Fatty liver is a risk factor for liver metastasis in Chinese patients

with non-small cell lung cancer. PeerJ. 2019;7.

[10]Wu B, Wu B, Wei S, Wei S, Tian J, Tian J, et al.

[Comparison of the Survival Time in the Non-small Cell Lung

Cancer Patients with Different Organ Metastasis]. Chin J Lung

Cancer. 2019;22:105–10.

[11]Tseng J-C, Tseng J-C, Chang L-C, Jiang B-Y, Liu

Y-C, Chen H-J, et al. Elevated circulating levels of tissue factor_xfffe_positive microvesicles are associated with distant metastasis in

lung cancer. J Cancer Res Clin Oncol. 2014;140:61–7.

[12]Wang C-F, Peng S-J, Liu R, Yu Y-J, Ge Q-M, Liang

R-B, et al. The Combination of CA125 and NSE Is Useful

for Predicting Liver Metastasis of Lung Cancer. Dis Markers.

2020;2020:8850873–8850873.

[13] 许田慧 , 刘宝刚 . 晚期肺癌肝转移的综合治疗进展 .

现代肿瘤医学 . 2019;27:2200–3.

[14]Kylie E Zane, Cloyd JM, Mumtaz K, Mumtaz K,

Wadhwa V, Wadhwa V, et al. Metastatic disease to the liver:

Locoregional therapy strategies and outcomes. World J Clin

Oncol. 2021;12:725–45.

[15]Zhong-Yi Zhang, An-Na Jiang, Wei Yang, Kun Yan,

Wei Wu, Song Wang, et al. Percutaneous Radiofrequency

Ablation Is an Effective Method for Local Control of Liver

Metastases From Lung Cancer. Front Oncol. 2022;12.

[16]G. Pacella, E. Faiella, C. Altomare, B. Zobel, R. Grasso.

Ablative Treatment of Hepatic Recurrence of Lung Cancer Using

Electrochemotherapy : A Case Report. Interv Med Clin Imaging.

[17] Yang J, Zhang Y, Sun X, Aaron M. Gusdon, Gusdon

AM, Song N, et al. The prognostic value of multiorgan metastases

in patients with non-small cell lung cancer and its variants: a

SEER-based study. J Cancer Res Clin Oncol. 2018;144:1835–

42.

[18]Ruhan Zhao, Yunnan Dai, Xinyang Li, Cuimin Zhu.

Construction and validation of a nomogram for non small cell

lung cancer patients with liver metastases based on a population

analysis. Sci Rep. 2022;12.